many clinical trials used 600 mg to 2 g/day
Using two groups (i.e., Semaglutide and Tirzepatide), two measurements (pre/post), a medium effect size (Cohens f = 0.25), alpha of 0.01, and 95% power, we required 76 participants
Conversely, Myo-inositol, which has been proposed as a dietary supplement for HT patients in recent years, has fewer reported clinical studies
DIRECTIONS: 6 MILLILITERS DAILY (just over one teaspoon) OR AS DIRECTED BY YOUR PHYSICIAN
We would further suggest that the approach is invalidated by the violation of a particular requirement of MR studies, i.e
The effects of exenatide and insulin glargine treatments on bone turnover markers and bone mineral density in postmenopausal patients with type 2 diabetes mellitus